For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Tolterodine - Overactive bladder (adults)
PAD Profile : Tolterodine - Overactive bladder (adults)
Traffic Light Status
Status 1 of 2.
- Immediate release tablets
Status 2 of 2.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Darifenacin hydrobromide
- Flavoxate hydrochloride
- Oxybutynin
- Propiverine hydrochloride
- Solifenacin
- Mirabegron
- Fesoterodine fumarate
- Trospium chloride
- Imipramine hydrochloride
Other Indications
No indications returned.
Additional Documents
Committee Recommendations
The APC supports patients in trialling a treatment break of their overactive bladder medicines.
A "Leaflet for trial of stopping anticholinergics" can be found in the documents section below.
Solifenacin is the 1st line treatment option.
Tolterodine immediate release is an alternative 1st line treatment option in patients with renal impairment (GFR <30mls/min)) and can be commenced at lower doses.
See Selection Tool for locally agreed OAB treatment options
Tolterodine modified release tablets are non-formulary. It was agreed by the APC that tolterodine MR can be switched to solifenacin (or an alternative formulary option) if approrpiate.